Ketone ester supplementation Update
Ketone ester supplementation attenuates seizure activity, and improves behavior and hippocampal synaptic plasticity in an Angelman syndrome mouse model
Towards Therapeutics – The FIRE Team Series, Part III
Read more about the exciting work that has earned the Segal Lab $1.1 Million for research.
FAST-Funded Research Leads To $1.1 Million Grant
Additional Gene Therapy Approach For Angelman Syndrome Explored By Paula Evans The Foundation for Angelman Syndrome Therapeutics (FAST) is delighted to annou
Towards Therapeutics – The FIRE Team Series, Part II
RDr. Dindot’s 3 goals, which have been the focus of his AS research through the FIRE initiative, are;
Mechanisms regulating imprinting of UBE3A in ne
Towards Therapeutics -The FIRE Team Series, Part IV
Dr Anne Anderson of the FAST FIRE team works on evaluating seizure and behavioral phenotypes (characteristics) in AS mice and how this information can be use
A Message To All Of Our Angelman STARS
Help Ovid Therapeutics Color Our World Beautiful! An Announcement from Ovid Therapeutics Ovid Therapeutics is working towards initiating its phase II study o
Towards Therapeutics – The FIRE Team Series, Part I
Edwin Weeber, Ph.D. is a Professor in the Department of Molecular Pharmacology and Physiology and the Chief Scientific Officer at the University of South Flo
Collaborating for Clinical Trials
Stakeholders meet to develop Biomarkers and Outcome Measures for clinical trials in Angelman Syndrome We are thrilled to announce that the Angelman Syndrome
Ketone esters for the treatment of seizures in AS – clinical trial coming soon!
Medical foods as an effective approach to management of Angelman Syndrome The following is a recount of a presentation about using therapeutic ketones (KES)
FAST Research Series
Read our regular series summarizing lectures presented on Friday December 4th, 2015, the first day of the 2015 FAST Global Summit. This series will be focuse